GLP-1 Peptides for Weight Loss: The Complete Guide

Weight loss drugs used to mean stimulants and appetite suppressants with thin evidence and rough side effects. That changed once researchers figured out how to copy a gut hormone the body already makes and turn it into a once weekly injection. This guide explains how those hormones work, which medications are actually FDA approved and for what, and which related compounds are still moving through clinical trials rather than sitting on pharmacy shelves.

What incretin hormones actually do

After you eat, cells in your gut release hormones called incretins. The main one for this topic is glucagon like peptide 1, almost always written as GLP-1. GLP-1 tells your pancreas to release insulin when blood sugar rises, slows the rate food leaves your stomach, and sends a fullness signal to appetite centers in the brain. In someone without metabolic disease, GLP-1 rises after a meal and fades within minutes because the body breaks it down fast.

GLP-1 receptor agonists are lab made molecules built to bind the same receptor but resist that fast breakdown. A single injection can keep receptor activity elevated for a full week instead of minutes. The practical effect is a person eats less without constantly fighting hunger, digestion slows so meals feel more filling, and blood sugar control improves. A related hormone, glucose dependent insulinotropic polypeptide, or GIP, works on a separate receptor and appears to add extra metabolic benefit when combined with GLP-1 activity, which is why some newer medications target both receptors at once.

None of this is a mystery mechanism. It is the reason these medications outperformed older appetite suppressants in trial after trial, and it is also why researchers keep testing new molecules that lean on the same biology.

It also explains the most common side effects reported across this entire class: nausea, slower digestion, and occasional constipation. Those effects trace directly back to the mechanism, a slower moving gut and a strong fullness signal, rather than to any one brand or dose. Most trials report that these effects are worst in the first few weeks after starting or increasing a dose and ease as the body adjusts, though a portion of participants in every trial still stop treatment because of them.

The medications with FDA approval

Three active ingredients in this category currently carry FDA approval, each sold under more than one brand name depending on the approved use. It matters which brand you are talking about, because the same drug can be approved for diabetes under one name and for weight management under another, at a different dose.

Semaglutide: Ozempic and Wegovy

Semaglutide is a GLP-1 receptor agonist approved by the FDA under the brand name Ozempic to improve blood sugar control in adults with type 2 diabetes, and under the brand name Wegovy for chronic weight management in adults with obesity, or with overweight plus at least one weight related condition such as high blood pressure. The Wegovy approval, granted in 2021, was the first new chronic weight management drug the FDA had cleared in years.

The evidence behind that approval is substantial. In the STEP 1 trial, published in the New England Journal of Medicine, adults with obesity or overweight who took semaglutide alongside lifestyle support lost close to 15 percent of their body weight on average over more than a year, compared with a small fraction of that in the placebo group. Semaglutide is also available as a once daily pill, a newer route that has expanded who can access this class of medication without an injection.

Tirzepatide: Mounjaro and Zepbound

Tirzepatide activates both the GLP-1 receptor and the GIP receptor, making it the first dual agonist to reach approval in this space. It is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management in adults with obesity or overweight and a weight related condition. The FDA approved Zepbound in November 2023, based largely on results from the SURMOUNT 1 trial.

That trial, also published in the New England Journal of Medicine, found that participants without diabetes lost between roughly 16 and 22 percent of body weight over the study period, depending on dose, again compared with a much smaller loss in the placebo arm. Because tirzepatide engages two hormone receptors instead of one, researchers point to it as early evidence that stacking incretin targets can outperform hitting GLP-1 alone, a pattern later compounds have tried to build on. A second trial in the same program, SURMOUNT 2, extended those findings to adults who also had type 2 diabetes, a group that tends to lose less weight on average than people without it.

Liraglutide: Victoza and Saxenda

Liraglutide is the oldest of the three, approved first as Victoza for type 2 diabetes and later as Saxenda for chronic weight management, including for adolescents age 12 and older with obesity. Where semaglutide and tirzepatide are dosed once weekly, liraglutide requires a daily injection, and its average weight loss in trials was more modest than the newer drugs, generally in the mid single digits as a percentage of body weight. It remains a real, currently prescribed option, just not the most potent one in its class.

Across all three, the pattern is the same: an approved indication tied to a specific brand name, a specific dose, and a specific patient population, decided by regulators after reviewing large controlled trials that ran for a year or longer and tracked thousands of participants. That is a meaningfully different bar than a compound that has only been tested in early stage research, and it is why an approved medication also comes with a manufacturer required label, a documented manufacturing process, and ongoing safety monitoring once it reaches pharmacies. None of that infrastructure exists yet for a compound still in trials, no matter how strong its early results look.

Compounds still moving through clinical trials

Beyond the three approved medications, a wider group of GLP-1 related compounds are being studied for weight loss and metabolic disease. None of them are FDA approved for any use as of this writing. They exist in various stages of clinical trials, and results so far are promising for several, but promising trial data is not the same thing as an approved drug with a label, a manufacturing standard, and years of postmarket safety tracking behind it.

Retatrutide is a triple agonist, engaging GLP-1, GIP, and glucagon receptors at once. In a phase 2 trial published in the New England Journal of Medicine, participants on the higher doses lost roughly a quarter of their body weight over 48 weeks, among the largest average reductions reported for any compound in this class so far. It has not completed the larger phase 3 trials the FDA requires before an approval decision.

Cagrilintide takes a different approach. Instead of targeting GLP-1 directly, it mimics amylin, a separate hormone involved in fullness and gastric emptying. On its own it is still investigational. Combined with semaglutide, it becomes CagriSema, a fixed dose pairing designed to hit both the GLP-1 and amylin pathways together. CagriSema has moved through several trials with encouraging weight loss data, but like cagrilintide alone, it does not yet have FDA approval.

Survodutide is a dual GLP-1 and glucagon receptor agonist in mid stage development, being studied for weight loss and for liver conditions linked to metabolic disease. Orforglipron stands out as an oral, non peptide GLP-1 receptor agonist, meaning it activates the same receptor as semaglutide but through a small molecule rather than a peptide chain, an approach that could simplify manufacturing if it clears trials. Mazdutide and pemvidutide are both dual GLP-1 and glucagon agonists in active trials, each with early data suggesting weight loss in a range similar to or exceeding tirzepatide, though again unconfirmed by a completed regulatory review.

Every one of these compounds deserves to be described accurately as research stage. Trial data that looks strong today can still change once a molecule is tested in larger, longer, more diverse populations, which is exactly what a full FDA review is built to check. A compound can post excellent phase 2 numbers and still stumble in phase 3, or clear phase 3 and still face a slower than expected review, so timelines for any of these reaching approval are genuinely unknown until the FDA makes a decision.

It is also worth separating two different research categories that get blended together online. Clinical trials for compounds like retatrutide or orforglipron are sponsored, monitored studies run by pharmaceutical companies under FDA oversight, with participants who consent to treatment and follow up care. That is a different setting from a research chemical purchased for laboratory use, which is not intended for human consumption and carries none of the oversight a clinical trial does. Reading about a compound's trial results is not the same as it being available, tested, or approved for personal use.

Comparing the mechanisms side by side

Laid out plainly, the receptor targets separate this group into a few tiers. Semaglutide and liraglutide work on GLP-1 alone. Tirzepatide, survodutide, mazdutide, and pemvidutide pair GLP-1 with a second hormone receptor, GIP for tirzepatide and glucagon for the other three. Retatrutide goes further and hits three receptors at once. Cagrilintide skips GLP-1 entirely in favor of the amylin pathway, and CagriSema combines that amylin action with GLP-1 by pairing it with semaglutide. Orforglipron reaches the GLP-1 receptor too, just through a different chemical route than the peptide based drugs.

The general trend across trials has been that adding receptor targets tends to increase average weight loss, though it can also change the side effect profile, and more targets is not automatically better for every person. Exact numbers vary by trial, dose, and population, which is why this guide keeps to rounded ranges rather than specific figures. If you want to work through actual reconstitution or dosing math for research purposes, the calculator is built for that and is a better tool than trying to eyeball it from an article.

Common questions

Is semaglutide the same thing as Ozempic or Wegovy? Yes. Semaglutide is the active ingredient. Ozempic and Wegovy are brand names for the same molecule at different approved doses and for different approved uses, diabetes for one and chronic weight management for the other.

Are retatrutide, cagrilintide, or orforglipron legal to buy? They are sold by research suppliers for laboratory and research use, not as approved medications for human treatment. None of them carry an FDA approval for any indication, so they are not available by prescription the way semaglutide or tirzepatide are.

Why do some GLP-1 compounds combine more than one hormone receptor? Researchers found that pairing GLP-1 activity with a second or third hormone pathway, such as GIP, glucagon, or amylin, tends to produce larger average weight loss in trials than targeting GLP-1 alone. Tirzepatide, retatrutide, and CagriSema are built around that idea, though each is still being evaluated in its own set of trials or, for tirzepatide, already carries approval.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.